290 related articles for article (PubMed ID: 22287653)
1. p16ink4a expression in benign and malignant melanocytic conjunctival lesions.
Zoroquiain P; Fernandes BF; González S; Novais GN; Schalper KA; Burnier MN
Int J Surg Pathol; 2012 Jun; 20(3):240-5. PubMed ID: 22287653
[TBL] [Abstract][Full Text] [Related]
2. [Immunohistochemical markers for cytoplasmic antigens in acquired melanosis, malignant melanomas, and nevi of the conjunctiva].
Hitzer S; Bialasiewicz AA; Richard G
Klin Monbl Augenheilkd; 1998 Oct; 213(4):230-7. PubMed ID: 9848068
[TBL] [Abstract][Full Text] [Related]
3. WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases.
Furusato E; Hidayat AA; Man YG; Auerbach A; Furusato B; Rushing EJ
Arch Ophthalmol; 2009 Aug; 127(8):964-9. PubMed ID: 19667332
[TBL] [Abstract][Full Text] [Related]
4. Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions.
Keijser S; Missotten GS; Bonfrer JM; de Wolff-Rouendaal D; Jager MJ; de Keizer RJ
Br J Ophthalmol; 2006 Feb; 90(2):213-7. PubMed ID: 16424536
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of nm23 H-1 protein in conjunctival melanoma and potential precursor lesions.
Seregard S; Oskarsson M; Spângberg B
Exp Eye Res; 1999 Dec; 69(6):671-6. PubMed ID: 10620396
[TBL] [Abstract][Full Text] [Related]
6. Chemokine Receptor Expression Pattern Correlates to Progression of Conjunctival Melanocytic Lesions.
van Ipenburg JA; de Waard NE; Naus NC; Jager MJ; Paridaens D; Verdijk RM
Invest Ophthalmol Vis Sci; 2019 Jul; 60(8):2950-2957. PubMed ID: 31305861
[TBL] [Abstract][Full Text] [Related]
7. Expression of sex hormone receptors and cell cycle proteins in melanocytic lesions of the ocular conjunctiva.
Pache M; Glatz-Krieger K; Sauter G; Meyer P
Graefes Arch Clin Exp Ophthalmol; 2006 Jan; 244(1):113-7. PubMed ID: 16003514
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical studies of conjunctival nevi and melanomas.
Jakobiec FA; Bhat P; Colby KA
Arch Ophthalmol; 2010 Feb; 128(2):174-83. PubMed ID: 20142539
[TBL] [Abstract][Full Text] [Related]
9. Differential immunoreactivity of melanocytic lesions of the conjunctiva.
Sharara NA; Alexander RA; Luthert PJ; Hungerford JL; Cree IA
Histopathology; 2001 Oct; 39(4):426-31. PubMed ID: 11683945
[TBL] [Abstract][Full Text] [Related]
10. PRAME expression by immunohistochemistry and reverse transcription quantitative PCR in conjunctival melanocytic lesions-a comprehensive clinicopathologic study of 202 cases and correlation of cytogenetics with PRAME expression in challenging conjunctival melanocytic lesions.
Mudhar HS; Milman T; Stevenson S; Watson M; Kim J; Magan T; Salvi SM; Harley U; Lally SE; Shields CL
Hum Pathol; 2023 Apr; 134():1-18. PubMed ID: 36804828
[TBL] [Abstract][Full Text] [Related]
11. Conjunctival nevi and melanoma: multiparametric immunohistochemical analysis, including p16, SOX10, HMB45, and Ki-67.
Milman T; Zhang Q; Ang S; Elder D; Ida CM; Salomao DR; Lally SE; Shields JA; Hamershock RA; Sioufi K; Shields CL; Eagle RC
Hum Pathol; 2020 Sep; 103():107-119. PubMed ID: 32707054
[TBL] [Abstract][Full Text] [Related]
12. The effect of the sun on expression of beta-catenin, p16 and cyclin d1 proteins in melanocytic lesions.
Demirkan NC; Kesen Z; Akdag B; Larue L; Delmas V
Clin Exp Dermatol; 2007 Nov; 32(6):733-9. PubMed ID: 17868395
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
Koopmans AE; Ober K; Dubbink HJ; Paridaens D; Naus NC; Belunek S; Krist B; Post E; Zwarthoff EC; de Klein A; Verdijk RM;
Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):6024-30. PubMed ID: 25159205
[TBL] [Abstract][Full Text] [Related]
14. PRAME immunohistochemistry is useful in the evaluation of conjunctival melanomas, nevi, and primary acquired melanosis.
LeBlanc RE; Miller DM; Zegans ME
J Cutan Pathol; 2021 Dec; 48(12):1442-1448. PubMed ID: 34089198
[TBL] [Abstract][Full Text] [Related]
15. C-Kit SCF receptor (CD117) expression and KIT gene mutation in conjunctival pigmented lesions.
Alessandrini L; Parrozzani R; Bertorelle R; Valentini E; Candiotto C; Giacomelli L; Midena E; Blandamura S
Acta Ophthalmol; 2013 Dec; 91(8):e641-5. PubMed ID: 23742652
[TBL] [Abstract][Full Text] [Related]
16. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
[TBL] [Abstract][Full Text] [Related]
17. Distinction of conjunctival melanocytic nevi from melanomas by fluorescence in situ hybridization.
Busam KJ; Fang Y; Jhanwar SC; Pulitzer MP; Marr B; Abramson DH
J Cutan Pathol; 2010 Feb; 37(2):196-203. PubMed ID: 20100177
[TBL] [Abstract][Full Text] [Related]
18. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
19. T1799A BRAF mutations in conjunctival melanocytic lesions.
Goldenberg-Cohen N; Cohen Y; Rosenbaum E; Herscovici Z; Chowers I; Weinberger D; Pe'er J; Sidransky D
Invest Ophthalmol Vis Sci; 2005 Sep; 46(9):3027-30. PubMed ID: 16123397
[TBL] [Abstract][Full Text] [Related]
20. Fascin expression in melanocytic lesions of the skin.
YILDIZ L; KEFELI M; AYDIN O; KANDEMIR B
Eur J Dermatol; 2009; 19(5):445-50. PubMed ID: 19527987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]